1.29

0.77% -0.01

After Hours: 1.30 0.01 +0.78%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.29, with a volume of 1.23M. It is down -0.77% in the last 24 hours and down -16.77% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.30

Open:

$1.3

24h Volume:

1.23M

Relative Volume:

1.01

Market Cap:

$321.59M

Revenue:

$14.56M

Net Income/Loss:

$-63.37M

P/E Ratio:

-4.6353

EPS:

-0.2783

Net Cash Flow:

$-19.44M

1W Performance:

+7.50%

1M Performance:

-16.77%

6M Performance:

-24.56%

1Y Performance:

+84.63%

1-Day Range:

$1.27

$1.34

1-Week Range:

$1.20

$1.365

52-Week Range:

$0.64

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-05-12

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.29	324.09M	14.56M	-63.37M	-19.44M	-0.2783
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

07:15 AM

Earnings Preview: LCTX to Report Financial Results Post-market on May 12 - Moomoo

May 21, 2026

May 20, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Investing News Network

May 20, 2026

May 18, 2026

Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX - FinancialContent

May 18, 2026

Lineage Cell Therapeutics, Inc. Common Stock (NYSE:LCTX) Stock Quote - FinancialContent

May 18, 2026

May 15, 2026

Lineage Cell Therapeutics Q1 Earnings Call Highlights - sharewise.com

May 15, 2026

May 14, 2026

Lineage Cell Therapeutics Q1 2026 earnings preview - MSN

May 14, 2026

Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies - Traders Union

May 14, 2026

Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives - Sahm

May 14, 2026

May 13, 2026

Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses - TipRanks

May 13, 2026

Q1 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus

May 13, 2026

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing - MSN

May 13, 2026

Lineage Cell (LCTX) reports Q1 loss, lags revenue estimates - MSN

May 13, 2026

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace

May 13, 2026

Lineage Cell Therapeutics (LCTX) Reports Q1 2026 Earnings and St - GuruFocus

May 13, 2026

TradingKey - TradingKey

May 13, 2026